Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when SYRE files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsSpyre Therapeutics raises $463.5M in public offering to fund Phase 3 readiness
Filed April 16, 2026 · Period ending April 14, 2026 · ~1 min read
Key Changes
-
high
Completed public offering of 7.475 million shares at $62/share, raising $463.5M gross proceeds before fees. Underwriters exercised full overallotment option.
Item 8.01 view on EDGAR → -
high
Proceeds will fund inflammatory bowel disease and rheumatic disease programs, including clinical trials, manufacturing, and Phase 3 readiness for antibody programs.
Item 8.01 view on EDGAR → -
high
Offering represents approximately 7.5 million new shares at $62, diluting existing shareholders but extending clinical development runway significantly.
Item 8.01 view on EDGAR → -
low
Syndicate led by Jefferies, Goldman Sachs, Evercore, and Guggenheim. Offering conducted via shelf registration effective February 27, 2026.
Item 8.01 view on EDGAR →
Summary
Spyre Therapeutics closed a $463.5 million public offering on April 16, 2026, selling 7.475 million shares at $62 each. The underwriters exercised their full overallotment option, indicating strong institutional demand.
The capital raise provides substantial funding for the company's inflammatory bowel disease and rheumatic disease programs, specifically targeting Phase 3 readiness activities for its antibody pipeline. For retail investors, this represents meaningful dilution—roughly 7.5 million new shares—but positions the company to advance multiple clinical programs without near-term financing risk.
The $62 offering price and full overallotment exercise suggest institutional confidence in the pipeline value. However, shareholders should monitor whether the share count increase pressures the stock price in coming weeks. Watch for updates on Phase 3 trial timelines and patient enrollment in the IBD and rheumatic disease programs, as these milestones will determine whether the capital deployment justifies the dilution. The company's next quarterly report should detail burn rate and updated cash runway.
Section-by-Section Diff
Event · Item 1.01 — Entry into a Material Definitive Agreement
Item 1.01 — Entry into a Material Definitive Agreement filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
On April 14, 2026, Spyre Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Jefferies LLC, Goldman Sachs & Co. LLC, Evercore Group L.L.C. and Guggenheim Securities, LLC, as the representatives of the underwriters named therein (the “Underwriters”), relating to the offer and sale (the “Offering”) of 6,500,000 shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), at a public offering price of $62.00 per share. In addition, the Company granted the Underwriters a 30-day option (the “Option”) to purchase up to an additional 975,000 shares of Common Stock on the same terms and conditions as the Common Stock sold in the Offering, which the Underwriters exercised in full on April 15, 2026. The Offering closed on April 16, 2026.
The company completed a public offering of 7.475 million shares (6.5M base plus 975K overallotment exercised in full) at $62 per share, closing April 16, 2026. The underwriters were Jefferies, Goldman Sachs, Evercore, and Guggenheim. This represents significant equity dilution but provides substantial capital.
Added in current filing · verify on EDGAR →
The gross proceeds to the Company from the Offering were approximately $463.5 million, before deducting underwriting discounts and commissions and estimated offering expenses. The Company intends to use the net proceeds of the offering to continue to advance its programs in inflammatory bowel disease and rheumatic diseases, including to fund preclinical studies, clinical trials, manufacturing, and Phase 3 readiness activities in support of its antibody programs, as well as for working capital and general corporate purposes.
The offering raised approximately $463.5 million in gross proceeds. Net proceeds will fund inflammatory bowel disease and rheumatic disease programs, including preclinical studies, clinical trials, manufacturing, and Phase 3 readiness activities for antibody programs, plus working capital and general corporate purposes. This capital extends the company's runway for clinical development.
Show 1 minor / wording change
Added in current filing · verify on EDGAR →
The Offering was made pursuant to the Company’s shelf registration statement on Form S-3 (File No. 333-293600), which was previously filed with the U.S. Securities and Exchange Commission (the “SEC”) on February 19, 2026, and became effective on February 27, 2026. A final prospectus supplement dated April 14, 2026, relating to and describing the terms of the Offering was filed with the SEC on April 16, 2026.
The offering was conducted under an existing shelf registration statement (File No. 333-293600) that became effective February 27, 2026. This is a standard takedown from a previously registered shelf, allowing the company to access capital markets efficiently.
Event · Item 9.01 — Financial Statements and Exhibits
Spyre Therapeutics executed an underwriting agreement with four investment banks on April 14, 2026, indicating a public securities offering.
Added in current filing · verify on EDGAR →
Underwriting Agreement, by and among the Company and Jefferies LLC, Goldman Sachs & Co. LLC, Evercore Group L.L.C. and Guggenheim Securities, LLC, dated as of April 14, 2026
Spyre Therapeutics entered into an underwriting agreement with four major investment banks on April 14, 2026. This typically indicates the company is conducting a public offering of securities to raise capital. The involvement of multiple underwriters suggests a significant financing transaction.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 2, 2026 · How we verify